Search

Your search keyword '"Downing, Amy"' showing total 542 results

Search Constraints

Start Over You searched for: Author "Downing, Amy" Remove constraint Author: "Downing, Amy"
542 results on '"Downing, Amy"'

Search Results

1. Weakly Supervised Text Classification on Free Text Comments in Patient-Reported Outcome Measures

3. Lake salinization drives consistent losses of zooplankton abundance and diversity across coordinated mesocosm experiments

5. Integrating Patient Reported Outcomes With Clinical Cancer Registry Data: A Feasibility Study of the Electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) System

6. The long and the short of it: Mechanisms of synchronous and compensatory dynamics across temporal scales

7. Current water quality guidelines across North America and Europe do not protect lakes from salinization

9. Alcohol use and adverse childhood experiences : does self-compassion play a mediating role?

21. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom

24. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study

31. Supplementary Figure 3 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

32. Supplementary Figure 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

33. Supplementary Figure 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

34. Table 3 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

35. Table 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

36. Supplementary Table 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

37. Data from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

38. Supplementary Table 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

39. Table 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

40. Figure 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

41. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial

42. Polymorphisms in Cyclooxygenase, Lipoxygenase and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention trial

44. Health‐related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year.

45. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial.

Catalog

Books, media, physical & digital resources